VP, Project Management
Mel was appointed VP, Project Management in 2019 having joined Kymab in 2015. Following a biological sciences degree at Oxford University, a PhD and then two post-docs, Mel spent 10 years in Research at MedImmune (the former Biologics Organisation of AstraZeneca and initially Cambridge Antibody Technology) first as a Senior Scientist in Antibody Engineering and then as a Project Manager working predominantly on immuno-oncology projects such as Imfinzi.
Mel moved into Development in 2010, working as a Senior Project Manager on autoimmune projects such as tralokinumab with global teams and Wuxi. Mel was also part of the MedImmune Cardiovascular Leadership Team. Mel is the Project Manager for Amlitelimab (anti-Ox40L) (SAR445229/KY1005). She is a Fellow of the Association of Project Management.